During the past decade, Consultants in Blood Disorders and Cancer conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 6 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Consultants in Blood Disorders and Cancer" #1 sponsor was "SCRI Development Innovations, LLC" with 23 trials, followed by "NSABP Foundation Inc" with 5 trials sponsored, "Chiron Corporation" with 2 trials sponsored, "CTI BioPharma" with 1 trials sponsored and "Celgene" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Consultants in Blood Disorders and Cancer" #1 collaborator was "Genentech, Inc." with 9 trials as a collaborator, "Bristol-Myers Squibb" with 5 trials as a collaborator, "Eli Lilly and Company" with 4 trials as a collaborator, "National Cancer Institute (NCI)" with 4 trials as a collaborator and "Novartis" with 4 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "Consultants in Blood Disorders and Cancer" are "Breast Cancer" (11 trials), "Lung Cancer" (4 trials), "Carcinoma, Small Cell" (2 trials), "Kidney Cancer" (2 trials) and "Lymphoma, Non-Hodgkin" (2 trials). Many other conditions were trialed in "Consultants in Blood Disorders and Cancer" in a lesser frequency.

Most popular intervention types in "Consultants in Blood Disorders and Cancer" are "Drug" (34 trials), "Procedure" (3 trials), "Biological" (2 trials), "Other" (2 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "Bevacizumab" (8 trials), "Carboplatin" (4 trials), "Gemcitabine" (4 trials), "Oxaliplatin" (4 trials) and "cyclophosphamide" (4 trials). Other intervention names were less common.

The vast majority of trials in "Consultants in Blood Disorders and Cancer" are 25 trials for "All" genders, 9 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Consultants in Blood Disorders and Cancer". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 32 completed trials in Consultants in Blood Disorders and Cancer, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Consultants in Blood Disorders and Cancer, 1 "Phase 1" clinical trials were conducted, 24 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".